A new study on S14G-humanin, a synthetic analog of the peptide humanin, was published on August 31, 2026. The publication, titled "S14G-humanin attenuates renal ischaemia-reperfusion injury, potentially through activation of STAT3 and ERK1/2 signalling pathways in rats," appeared in the journal Experimental Physiology.
The study is listed under publication ID 42672739 and is available via PubMed. According to the title, the research examines the effects of S14G-humanin on renal ischaemia-reperfusion injury in a rat model, with a focus on STAT3 and ERK1/2 signalling pathways.
Humanin remains classified as an unapproved compound intended for research purposes only. This publication represents an addition to the scientific literature on humanin and its analogs and does not constitute regulatory approval or endorsement of any therapeutic use. No dosing information, clinical application guidance, or efficacy claims beyond the study title are provided here.
Readers interested in the broader context of humanin research, including its regulatory status and other published findings, can consult the compound overview for additional background.